BOESS CARSTEN 4

What Happened Carsten Boess, a director of Rocket Pharmaceuticals (RCKT), received equity awards on June 18, 2026: 22,862 restricted stock units (RSUs) reported at $0.00 and a derivative award representing the right to purchase 64,860 shares (reported at $0.00). The total potential equity from these grants is 87,722 shares. These were grants/awards (transaction code A), not open-market purchases or sales.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-07-06 (filed 18 days after the transaction).
• Reported price: $0.00 for both items (standard for grant/award reporting).
• Shares after transaction: not specified in the filing.
• Footnotes:
  • F1: RSUs convert one-for-one to common stock and will vest in full on June 18, 2027.
  • F2: The option is a right to purchase 64,860 shares; it will become fully vested and exercisable on June 18, 2027.
• Timeliness: The Form 4 was filed 18 days after the grant date, which is later than the typical 2-business-day deadline for insider Form 4 filings.

Context These awards are compensation grants that vest in one year (both RSUs and the option become vested/exercisable on 2027-06-18). RSUs convert directly into shares at vesting; the option grant gives the right to buy shares once vested (the filing does not state an exercise price). Awards like these are routine director compensation and do not represent an immediate buy/sell signal; investors should note potential future dilution if the option is exercised or RSUs vest.